

Kieran Murphy, President & CEO GE Healthcare

9 January 2018

Confidential. Not to be copied, reproduced, or distributed without prior approval.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS:

This document contains "forward-looking statements" – that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. For details on the uncertainties that may cause our actual future results to be materially different than those expressed in our forward-looking statements, see

http://www.ge.com/investor-relations/disclaimer-caution-concerning-forwardlooking-statements as well as our annual reports on Form 10-K and quarterly reports on Form 10-Q. We do not undertake to update our forward-looking statements. This document also includes certain forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially.

This is GE Healthcare


Impact	Leader in Imaging & Mobile Diagnostics	Leader in China and Emerging Markets	Leader in Data and Analytics	Leader in Life Sciences
	1MM+ Installed Base 16K+ Scans every minute	Portfolio breadth GE scale	230MM exams 124K assets under management	Biologics and Cell Therapies

At Scale	Revenue	Op Profit	OP%	FCF Conv.
'16A	\$18.3B	\$3.2B	17.3%	> 100%
'17 3Q YTD	+4%	+7%	+60bps	> 100%



A leading healthcare solutions provider

(\$B Revenue)



DIAGNOSTIC IMAGING & SERVICE

Magnetic Resonance

Computed Tomography

Molecular Imaging

Service & Solutions

\$8B



MOBILE DIAGNOSTICS & MONITORING

Ultrasound

Clinical Solutions

Monitoring

Mobile Health

\$4B



IT & DIGITAL SOLUTIONS


Enterprise Imaging

Financial Management

Care Area Workflows

GE Health Cloud™

\$2B



LIFE SCIENCES

Bioprocess

Protein & Cell Sciences

Contrast Media & Nuclear Tracers

Cell Therapy

\$5B



Key themes in healthcare market today



Patient outcomes



Productivity, efficiency



Emerging markets access



Competitive cost position



Precision health

Precision health: Better outcomes, delivered more efficiently

Enabling precision health

Precision diagnostics

Precision therapeutics

Precision monitoring

In-Vivo + In-Vitro

Decision making

Therapy innovation

Therapy delivery

Monitoring











From



To

Highly personalized

Protocol driven

Fragmented, manual

Integrated and fueled by AI

Costly & risky

Precisely targeted clinical trials

Complex, unguided

Industrialized.
Precise. Additive

Focused on the sick

Health focused, outside hospital

Unique combination of leadership in Dx, digital, providers, and biopharma tools



Product and technology leadership

tech, superior Dx

accuracy

MR **CELL ULTRASOUND WOMEN'S AFFORDABLE CONTRAST DIGITAL** HEALTH **THERAPY CARE IMAGING** 3.0T Architect **Revolution ACT** Biosafe Clariscan **Venue POC Senographe Pristina** PACS/ RIS Increased range Next gen Improved design Cutting edge Intuitive user Improved image Expanding Universal of MRI contrast for patient and 3.0T wide-bore exp. in simple, quality with into new cell

reduced dose



driven by total

digital Imaging

fast tablet

Viewer

media

and therapy

types

Leading outcome based solutions

DIGITAL SOLUTIONS

Command Center



Patient impact

18 systems, 15 apps...on 24/7

28% ↓ ER wait time

48% ↓ Xfer out of PACU

70% ↓ OR transfer delays

OUTCOME BASED SOLUTIONS

Turkey PPP



Increasing access

+8,000 hospital beds to Turkey's public health system

\$225M in orders for GEHC 25 year partnership

INFRASTRUCTURE

KUBio and GE Biopark



Creating capacity

Faster time-to-market
Greater optionality

MANAGED SERVICES

GE-to-country: Kenya



Healthcare transformation

Modernize radiology infrastructure (equip, serv., training) for 98 hospitals

~\$200M in orders for GEHC 10 year partnership



Disciplined capital allocation

Approach

ORGANIC

Differentiated R&D, disciplined cost control (SG&A \checkmark 2 pts), restructuring, product cost out

INORGANIC

Strategic M&A, 'bolt on' targets, low ROIC exits

OPERATING IMPERATIVES

Productivity ... expanding value-gap, cash flow intensity: 100%+ FCF / NI

STRATEGIC PRIORITIES

Biopharma, cell therapy, enterprise imaging, digitally-connected workflows & solutions, patient-focused technology R&D

Defined investment strategy, higher margins, growth momentum



Investing in the core

R&D Programs

- ✓ Product cost out
- ✓ Digital + solutions
- ✓ NPI launches 2X

Core

DESIGN Simplified designs ... margins to GE

300+ cost out engineers ... NPI cost

TECHNOLOGY Market-backed technologies ... drives share

Increasing speed to address customer needs

AFFORDABLE Value/Super Value portfolio

CARE LCC engineering COE's ... productivity

DIGITAL Customer experience + productivity

Connected infrastructure: service, upgrades



Investing in new growth platforms

Cycling our portfolio into fast-growth segments

ON SYSTEMS	ON	S	ST	EI	VI	3
------------	----	---	-----------	----	----	---

Asset Performance Management, Smart devices (Helix Advanced Image Processing)

IN THE CLOUD

Centricity Imaging Collaboration Suite, Algorithms-as-a-Service

ANALYTICS

200+ Apps live ... Imaging analytics, Command Center, Alarm management, many more

ADDITIVE

50+ active projects, IDAMT Center (Uppsala), GE Additive + Stryker partnerships

CELL THERAPY

Industrializing workflows, double-digit growth, Biosafe and Asymptote acquisitions



Partnerships as an accelerator







Advanced analytics & clinical decision support

A pioneering new partnership





Medical imaging
Patient monitoring
Digital & analytics
Solutions

Early diagnosis, early intervention, individualized treatments



Summary



Industry leader with great platforms ... Imaging, Life Sciences, Monitoring, Digital, Services



Well run business with disciplined capital allocation and operating rigor



Scale, global reach, connectedness



Heritage of technology innovation that delivers patient outcomes



Positioned for growth



Thank you

